Understanding how specific proteins affect leukemia in children
Official title: Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia
Funded at Dana-Farber Cancer Inst · NIH-11061333 · Data updated 2026-11-12
This study is looking at how certain proteins linked to leukemia in kids affect cancer growth, and it hopes to find new ways to treat young patients by seeing what happens when these proteins are removed.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $215,179 |
| NIH project number | 5K08CA279891-02 |
| Project ID | NIH-11061333 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years diagnosed with acute myeloid leukemia, particularly those with NUP98 rearrangements.
✕Less likely to help
Patients with other types of leukemia or those outside the specified age range may not benefit from this research.
What this research studies
This research investigates the role of NUP98-fusion proteins in acute myeloid leukemia (AML), particularly in children. It aims to understand how these proteins interact with chromatin modifying enzymes to drive cancer progression. By using a novel mouse model, researchers will explore the immediate effects of degrading these fusion proteins on gene expression and chromatin structure. The goal is to identify potential therapeutic targets that could improve treatment outcomes for young patients with NUP98-rearranged leukemia.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates for children with specific types of leukemia.
How similar studies have gone: Previous research has shown promising results in targeting chromatin interactions in leukemia, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Heikamp, Emily — Dana-Farber Cancer Inst
- Study coordinator: Heikamp, Emily
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.